Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen

AIDS

Volumn 16, Issue 1, 2002, Pages 21-29

  Le Moing, Vincent ^a   Chêne, Geneviève ^a   Carrieri, Maria P ^a   Alioum, Ahmadou ^a   Brun Vézinet, Françoise ^a   Piroth, Lionel ^a   Cassuto, Jill P ^a   Moatti, Jean Paul ^a   Raffi, François ^a   Leport, Catherine ^a   Salamon, R ^a   Pierret, J ^a   Fleury, H ^a   Peytavin, G ^a   Costagliola, D ^a   Dellamonica, P ^a   Katlama, C ^a   Meyer, L ^a   Morin, M ^a   Sicard, D ^a   Sobel, A ^a   Vincent Ballereau, F ^a   Dupon, M ^a   Marchou, B ^a   May, T ^a   Morlat, P ^a   Waldner Combernoux, A ^a   Bach, M A ^a   Bourdillon, F ^a   Delfraissy, J F ^a   Dormont, J ^a   Portier, H ^a   Souteyrand, Y ^a   Vilde J L ^a   Schmit, J L ^a   Chennebault, J M ^a   Faller, J P ^a   Estavoyer, J M ^a   Laurent, P ^a   Vuitton, P ^a   Beylot, J ^a   Le Bras, M ^a   Ragnaud, J M ^a   Granier, P ^a   Garre M ^a   Bazin, C ^a   Veyssier, P ^a   Devidas, A ^a   Perrone, C ^a   Lagarde, P ^a   Ceccaldi, J ^a   Peyramond, D ^a   Allard, C ^a   Reynes, J ^a   Cassuto, J P ^a   Arsac, P ^a   Bouvet, E ^a   Bricaire, F ^a   Caulin, C ^a   Frottier, J ^a   Herson, S ^a   Imbert, J C ^a   Malkin, J E ^a   Rozenbaum, W ^a   Becq Giraudon, B ^a   Remy G ^a   Michelet, C ^a   Lucht, F ^a   Roue R ^a   Lang, J M ^a   De Jaureguiberry, J P ^a   Massip, P ^a   Choutet, P ^a   Alfaro, C ^a   Barennes, C ^a   Boucherit, S ^a   Cailleton, V ^a   Duran, S ^a   Ecobichon, J L ^a   Egouy, C ^a   Journot, V ^a   Lassale, R ^a   Latour, L ^a   Lewden, C ^a   Masquelier, B ^a   Nouioua, W ^a   Palmer, G ^a   Roloff, S ^a   Saves M ^a   Spire, B ^a   Souville, M ^a   Surzyn, J ^a   Winum, R ^a   more..

^a BICHAT HOSPITAL   (France)

Author keywords

Adherence to therapy; HIV 1; Plasma HIV RNA; Protease inhibitor; Virological rebound

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; AGE; AGED; ARTICLE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; REBOUND; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; PATIENT COMPLIANCE; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD;

EID: 0037016424     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200201040-00004     Document Type: Article

References (27)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with Human Immunodeficiency Virus infection and CD4 counts of 200 per cubic millimeter or less
2. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
3. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor
4. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
5. Virological response to protease inhibitor in an HIV clinic cohort
6. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load
7. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe. Results from the EuroSIDA study
8. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
9. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
10. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
11. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
12. Human immunodeficiency virus 1 protease inhibitors in clinical practice: Predictors of virological outcome
13. Definition of virological response and the type of assay used for quantification of viral load may influence the proportion of responders to antiretroviral therapy
14. PHMPL: A computer program for hazard estimation using a penalized likelihood method with interval-censored and left-truncated data
15. Adherence to protease inhibitors, HIV-viral load, and development of drug resistance in an indigent population
16. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor
17. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
18. Time to initiation of antiretroviral therapy: Impact on HIV-1 viraemia
19. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus-1 protease, to treat HIV infection
20. Predictors of optimal virological response to potent antiretroviral therapy
21. Nelfinavir. An update on its use in HIV infection
22. A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients
23. Correlates of durable treatment success among long-term highly active antiretroviral recipients in the HIV outpatient study
24. Survivor treatment bias in observational studies: Examples from the AIDS literature
25. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: Comparison of cohort studies with randomized trials
26. Clinical progression of HIV-1 infection according to the viral response in the first year of antiretroviral treatment
27. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection